Clinical Utility of Adjuvant Growth Hormone in the Treatment of Patients with Polycystic Ovaries Undergoing In Vitro FertilizationPolycystic ovarian disease .(PCOD) is a multifactorial endocrinopathy characterized by a wide range of variable manifestations such as oligoamenorrhea, clinical and biochemical signs of hyperandrogenism and hyperinsulinemia, a tendency to obesity, and typical ultrasound features. The identification of PCOD presents a number of difficulties and requires comprehensive clinical, ultrasonographic, morphological, and biochemical data. The clinical data include menstrual cycle disorders, ache, hirsutism, obesity, and metabolic manifestations of insuline resistance. Biochemical data include hyperandrogenism, an increased luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratio, and insulin resistance.The treatment of PCOD with associated infertility remains a problem. The antiestrogen, clomiphene citrate (CC), is the drug of first choice. Ovulation can be induced in about 75-80% of women with PCOD treated with CC; however, the overall pregnancy rate is only 30-40%. The use of exogenous gonadotropins in PCOD patients is a more acceptable treatment for CC-resistant patients, with an overall pregnancy rate of 66%. However, this is associated with a high rate of multiple pregnancies and spontaneous abortions and a greater risk of ovarian hyperstimulation syndrome (OHSS). Purified urinary FSH, it is claimed, produces a lower incidence of OHSS. Cotreatment with gonadotropin releasing hormone analogue (GnRH-a) and human menopausal